Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-19
2011-04-19
Havlin, Robert (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S378000
Reexamination Certificate
active
07928244
ABSTRACT:
The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
REFERENCES:
patent: 5294617 (1994-03-01), Venkatesan et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 6221865 (2001-04-01), Sebti et al.
patent: 6747050 (2004-06-01), Kim et al.
patent: 3643012 (1988-06-01), None
patent: 0769296 (1997-04-01), None
patent: 0970950 (2000-01-01), None
patent: 11343285 (1999-12-01), None
patent: WO-95/24398 (1995-09-01), None
patent: WO-9806694 (1998-02-01), None
patent: WO-9816830 (1998-04-01), None
patent: WO-0116115 (2001-03-01), None
patent: WO-02/097053 (2002-12-01), None
patent: WO-03105788 (2003-02-01), None
patent: WO 2006/009869 (2006-01-01), None
patent: WO-2006/009869 (2006-01-01), None
Akmanova, N. A. et al., “Dipolar Addition to Carbamoyl Nitrones”,Zhurnal Organicheskoi Khimii, 15(10):2061-2065 (Oct. 1979) (English translation).
Baell, J. et al., “Prospects for targeting the Bcl-2 family of proteins to develope novel cytotoxic drugs”,Biochem. Pharmacol., 64:851-863 (2002).
Banerji, A. et a., “1,3-Dipolar cycloadditions: Part VII—Cycloaddition of C,N-diarylnitrones to ethyl crotonate”, Ind. Journ. of Chem., 43B:1925-1933 (Sep. 2004).
Ding, X. et al., “Catalytic Asymmetric 1,3-Dipolar Cycloaddition of a Nitrone Bearing a Bulky Amide Moiety to γ-Substituted Allylic Alcohols”,Chemistry Letters, 2002:302-303 (2002).
Dugovic, B., et al., “Reversal of Regioselectivity of Nitrone Cycloadditions by Lewis Acids”, Helvetica Chimica Acta, 88:1432-1443 (2005).
Foley, M., “Infinity Pharmaceuticals—Infiniplex Libraries: Developing a Platform for Chemical Genetic Studies”, PowerPoint Presentation Oct. 2, 2006.
Foley, M., “Infinity Pharmaceuticals—Chemical Genomics-Linking the Genome to Therapies”, PowerPoint Presentation Jun. 11, 2002.
Foley, M., “Infinity Pharmaceuticals—ACS Short Course on Drug Discovery in the 21st Century—Arrayed Split-Pool Libraries: Developing a Platform for Chemical Genetic Studies”, PowerPoint Presentation Jul. 10, 2002.
“Infinity Pharmaceuticals—ACS Prospectives Conference Series”, PowerPoint Presentation Sep. 22, 2003.
“Infinity Pharmaceuticals—Cambridge Health Institute's Conference on Diversity-Oriented Synthesis (DOS) and Natural Product Chemistry”, PowerPoint Presentation Oct. 9, 2003.
Inouye, Y., et al., “Regioselective Effects of the Allylic Heteroatoms in 1,3-Dipolar Cycloaddition of Nitrones to Several Allyl Derivatives”, Heterocycles, 25:109-111 (1987).
Jen, W. S., et al., “New Strategies for Organic Catalysis: The First Enantioselective Organocatalytic 1,3-Dipolar Cycloaddition”, J. Am. Chem. Soc., 122:9874-9875 (2000).
Kanemasa, S. et al., “Metal Ion-Mediated Diastereoface-Selective Nitrone Cycloadditions. Reaction Mechanism for the Reversal of Regioselectivity Observed in the Magnesium and Zinc Ion-Mediated Nitrone Cycloadditions of Allylic Alcohols”, Tetrahedron Letters, 36(28):5019-5022 (1995).
Kanemasa, S. et al., “Metallic Base-Induced and Lewis Acid-Catalyzed Nitrone Cycloadditions to Allyl Alcohol Dipolarophiles. Highly Effective Regio- and Stereocontrol”, Tetrahedron Letters, 34(1):87-90 (1993).
Kano, T. et al., “Asymmetric 1,3-Dipolar Cycloaddition Reaction of Nitrones and Acrolein with a Bis-Titanium Catalyst as Chiral Lewis Acid”, J. Am. Chem. Soc., 127:11926-11927 (2005).
Merino, P. et al., “1,3-Dipolar Cycloadditions of N-Benzyl Furfuryl Nitrones with Electron-rich Alkenes”, Molecules, 5:132-152 (2000).
Merino, P. et al., “A DFT Study on the 1,3-Dipolar Cycloaddition Reactions of C-(methylcarbonyl)-N-methyl nitrone with methyl acrylate and vinyl acetate”, Tetrahedron, 59:3581-3592 (2003).
Niu, D. et al., “Non-Cycloaddition Approach to Regioselective Synthesis of Isoxazolidines”, Synlett, 979-980 (Sep. 1998).
Puglisi, A. et al., “Enantioselective 1,3-Dipolar Cycloadditions of Unsaturated Aldehydes Promoted by a Poly(ethylene glycol)-Supported Organic Catalyst”, Eur. J. Org. Chem., 567-573 (2004).
Ratts, K. W. et al., “Chemistry of Resonance-Stabilized Sulfonium Ylids”,Journal of Organic Chemistry, 31(6):1689-1693 (1966).
Revuelta, J. et al., “Samarium(II) iodide reduction of isoxazolidines”, Tetrahedron Letters, 45:8375-8377 (2004).
Saito, T. et al., “Evaluation of chiral bidentate ligand-metal complexes in asymmetric 1,3 dipolar cycloaddition reaction of nitrones with 3-alkenoyl-2-oxazolidinones”, Tetrahedron Letters, 45:9581-9584 (2004).
Sibi, M. P. et al., “Exo Selective Enantioselective Nitrone Cycloadditions”, J. Am. Chem. Soc., 126:718-719 (2004).
Tan, D. S. et al., “Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays”,J. Am. Chem. Soc., 12:08565-8566 (1998).
Byrn, S. et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,”Pharmaceutical Research, 12(7):945-954 (Plenum Publishing, USA) (1995).
Kubinyi, E. H. (ED QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages).
Blanáriková-Hlobilová, I. et al., “Stereoselectivity of 1,3-dipolar cycloadditions of L-valine-derived nitrones with methyl acrylate”, Tetrahedron 59, 3333-3339 (2003).
International Search Report for PCT/US2007/018471 dated Feb. 25, 2008.
International Search Report for PCT/US2007/023941 dated Feb. 28, 2008.
Castro Alfredo C.
Depew Kristopher M.
Grogan Michael J.
Holson Edward B.
Hopkins Brian T.
Foley & Hoag LLP
Havlin Robert
Infinity Discovery, Inc.
LandOfFree
Compounds and methods for inhibiting the interaction of BCL... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for inhibiting the interaction of BCL..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for inhibiting the interaction of BCL... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704224